Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1α) in Waldenström macroglobulinaemia

British Journal of Haematology

Volumn 133, Issue 3, 2006, Pages 301-304

  Terpos, Evangelos ^a,b,d   Anagnostopoulos, Athanasios ^c   Kastritis, Efstathios ^c   Bamias, Aristotelis ^c   Tsionos, Konstantinos ^a   Dimopoulos, Meletios Athanassios ^c  

^a General Airforce Hospital   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Bone markers; Macrophage inflammatory protein 1 alpha; Osteoprotegerin; Receptor activator of nuclear factor B ligand; Waldenstr m macroglobulinaemia

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BETA 2 MICROGLOBULIN; CARBOXY TERMINAL TELOPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE REMODELING; CLINICAL ARTICLE; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; FEMALE; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED; SPLENOMEGALY; WALDENSTROM MACROGLOBULINEMIA;

EID: 33645450317     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06017.x     Document Type: Article

References (12)

1. International Myeloma Working Group 2003 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 121 749 757.
2. Marcelli C. Chappard D. Rossi J.F. Jaubert J. Alexandre C. Dessauw P. Baldet P. Bataille R. 1988 Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer 62 1163 1170.
3. Menten P. Saccani A. Dillen C. Wuyts A. Struyf S. Proost P. Mantovani A. Wang J.M. Van Damme J. 2002 Role of the autocrine chemokines MIP-1alpha and MIP-1beta in the metastatic behavior of murine T cell lymphoma. Journal of Leukocyte Biology 72 780 789.
4. Moulopoulos L.A. Dimopoulos M.A. Varma D.G. Alexanian R. 1993 Waldenstrom's macroglobulinemia: MR imaging of the spine and computed tomography of the abdomen and pelvis. Radiology 188 669 673.
5. Oyajobi B.O. Franchin G. Williams P.J. Pulkrabek D. Gupta A. Munoz S. Grubbs B. Zhao M. Chen D. Sherry B. Mundy G.R. 2003 Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102 311 319.
6. Politou M. Terpos E. Anagnostopoulos A. Szydlo R. Laffan M. Layton M. Apperley J.F. Dimopoulos M.A. Rahemtulla A. 2004 Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1α) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology 126 686 689.
7. Rothschild B.M. Ruhli F. Rothschild B.M. 2002 Skeletal clues apparently distinguishing Waldenstrom's macroglobulinemia from multiple myeloma and leukaemia. American Journal of Human Biology 14 532 537.
8. Shibata H. Abe M. Hiura K. Wilde J. Moriyama K. Sano T. Kitazoe K. Hashimoto T. Ozaki S. Wakatsuki S. Kido S. Inoue D. Matsumoto T. 2005 Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappa B ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clinical Cancer Research 11 6109 6115.
9. Tedla N. Palladinetti P. Wakefield D. Lloyd A. 1999 Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11 531 540.
10. Terpos E. Politou M. Szydlo R. Goldman J.M. Apperley J.F. Rahemtulla A. 2003 Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 123 106 109.
11. Terpos E. Mihou D. Szydlo R. Tsimirika K. Karkantaris C. Politou M. Voskaridou E. Rahemtulla A. Dimopoulos M.A. Zervas K. 2005 The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 19 1969 1976.
12. Tian E. Zhan F. Walker R. Rasmussen E. Ma Y. Barlogie B. Shaughnessy Jr. J.D. 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine 349 2483 2494.